Cargando…
Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
Aims/Introduction: Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes. Materials and Methods: Seru...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015428/ https://www.ncbi.nlm.nih.gov/pubmed/24843614 http://dx.doi.org/10.1111/j.2040-1124.2012.00220.x |
_version_ | 1782315336581775360 |
---|---|
author | Senmaru, Takafumi Fukui, Michiaki Kobayashi, Kanae Iwase, Hiroya Inada, Shinobu Okada, Hiroshi Asano, Mai Yamazaki, Masahiro Hasegawa, Goji Nakamura, Naoto Iwasaki, Masahiro Yabe, Daisuke Kurose, Takeshi Seino, Yutaka |
author_facet | Senmaru, Takafumi Fukui, Michiaki Kobayashi, Kanae Iwase, Hiroya Inada, Shinobu Okada, Hiroshi Asano, Mai Yamazaki, Masahiro Hasegawa, Goji Nakamura, Naoto Iwasaki, Masahiro Yabe, Daisuke Kurose, Takeshi Seino, Yutaka |
author_sort | Senmaru, Takafumi |
collection | PubMed |
description | Aims/Introduction: Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes. Materials and Methods: Serum EPA concentrations were measured in 62 consecutive patients with type 2 diabetes who were newly given DPP‐4 inhibitor as a monotherapy or as an add‐on therapy to oral hypoglycemic agents. The dosage of oral hypoglycemic agents was maintained during the observation period. After 24 weeks of treatment with DPP‐4 inhibitor, we evaluated the relationships between a decrease in hemoglobin A1c from baseline and serum EPA concentrations, as well as age, sex, body mass index (BMI), hemoglobin A1c at baseline and usage of antidiabetic concomitant drugs. Results: Hemoglobin A1c was significantly decreased from 8.1 ± 1.1% to 7.2 ± 1.0% by DPP‐4 inhibitor. A decrease in hemoglobin A1c correlated with BMI (r = −0.396, P = 0.0013), age (r = 0.275, P = 0.0032), hemoglobin A1c at baseline (r = 0.490, P < 0.0001) and log EPA (r = 0.285, P = 0.0246). Multiple regression analysis showed that BMI (β = −0.419, P = 0.0002), hemoglobin A1c at baseline (β = 0.579, P < 0.0001) and log EPA (β = 0.220, P = 0.0228) were independent determinants of decrease in hemoglobin A1c. Conclusions: DPP‐4 inhibitor is effective in patients with type 2 diabetes with high serum EPA concentrations. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00220.x , 2012) |
format | Online Article Text |
id | pubmed-4015428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-40154282014-05-19 Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations Senmaru, Takafumi Fukui, Michiaki Kobayashi, Kanae Iwase, Hiroya Inada, Shinobu Okada, Hiroshi Asano, Mai Yamazaki, Masahiro Hasegawa, Goji Nakamura, Naoto Iwasaki, Masahiro Yabe, Daisuke Kurose, Takeshi Seino, Yutaka J Diabetes Investig Articles Aims/Introduction: Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes. Materials and Methods: Serum EPA concentrations were measured in 62 consecutive patients with type 2 diabetes who were newly given DPP‐4 inhibitor as a monotherapy or as an add‐on therapy to oral hypoglycemic agents. The dosage of oral hypoglycemic agents was maintained during the observation period. After 24 weeks of treatment with DPP‐4 inhibitor, we evaluated the relationships between a decrease in hemoglobin A1c from baseline and serum EPA concentrations, as well as age, sex, body mass index (BMI), hemoglobin A1c at baseline and usage of antidiabetic concomitant drugs. Results: Hemoglobin A1c was significantly decreased from 8.1 ± 1.1% to 7.2 ± 1.0% by DPP‐4 inhibitor. A decrease in hemoglobin A1c correlated with BMI (r = −0.396, P = 0.0013), age (r = 0.275, P = 0.0032), hemoglobin A1c at baseline (r = 0.490, P < 0.0001) and log EPA (r = 0.285, P = 0.0246). Multiple regression analysis showed that BMI (β = −0.419, P = 0.0002), hemoglobin A1c at baseline (β = 0.579, P < 0.0001) and log EPA (β = 0.220, P = 0.0228) were independent determinants of decrease in hemoglobin A1c. Conclusions: DPP‐4 inhibitor is effective in patients with type 2 diabetes with high serum EPA concentrations. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00220.x , 2012) Blackwell Publishing Ltd 2012-05-22 2012-12-20 /pmc/articles/PMC4015428/ /pubmed/24843614 http://dx.doi.org/10.1111/j.2040-1124.2012.00220.x Text en © 2012 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd |
spellingShingle | Articles Senmaru, Takafumi Fukui, Michiaki Kobayashi, Kanae Iwase, Hiroya Inada, Shinobu Okada, Hiroshi Asano, Mai Yamazaki, Masahiro Hasegawa, Goji Nakamura, Naoto Iwasaki, Masahiro Yabe, Daisuke Kurose, Takeshi Seino, Yutaka Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations |
title | Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations |
title_full | Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations |
title_fullStr | Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations |
title_full_unstemmed | Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations |
title_short | Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations |
title_sort | dipeptidyl‐peptidase iv inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015428/ https://www.ncbi.nlm.nih.gov/pubmed/24843614 http://dx.doi.org/10.1111/j.2040-1124.2012.00220.x |
work_keys_str_mv | AT senmarutakafumi dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT fukuimichiaki dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT kobayashikanae dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT iwasehiroya dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT inadashinobu dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT okadahiroshi dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT asanomai dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT yamazakimasahiro dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT hasegawagoji dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT nakamuranaoto dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT iwasakimasahiro dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT yabedaisuke dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT kurosetakeshi dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations AT seinoyutaka dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations |